BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36672611)

  • 1. Gene Therapy with Voretigene Neparvovec Improves Vision and Partially Restores Electrophysiological Function in Pre-School Children with Leber Congenital Amaurosis.
    Gerhardt MJ; Priglinger CS; Rudolph G; Hufendiek K; Framme C; Jägle H; Salchow DJ; Anschütz A; Michalakis S; Priglinger SG
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
    Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
    Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
    Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
    Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.
    Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K
    Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee.
    Han J; Joo K; Kim US; Woo SJ; Lee EK; Lee JY; Park TK; Kim SJ; Byeon SH
    Korean J Ophthalmol; 2023 Apr; 37(2):166-186. PubMed ID: 36950921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral exudative retinal detachments after subretinal gene therapy with voretigene neparvovec-rzyl for RPE65 Leber Congenital Amaurosis.
    Lidder AK; Choi S; Modi YS; Brodie SE; Davis JL; Gregori NZ; Lam BL
    Am J Ophthalmol Case Rep; 2023 Dec; 32():101879. PubMed ID: 37521805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
    Hussain RM; Tran KD; Maguire AM; Berrocal AM
    Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy in Hereditary Retinal Dystrophies: The Usefulness of Diagnostic Tools in Candidate Patient Selections.
    Malvasi M; Casillo L; Avogaro F; Abbouda A; Vingolo EM
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
    Kang C; Scott LJ
    Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
    Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
    Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
    Kolesnikova M; Lima de Carvalho JR; Parmann R; Kim AH; Mahajan VB; Tsang SH; Sparrow JR
    Mol Genet Genomic Med; 2022 Nov; 10(11):e2038. PubMed ID: 36225124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
    Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
    Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first gene therapy for
    Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
    Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.
    Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A
    JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voretigene Neparvovec and Gene Therapy for Leber's Congenital Amaurosis: Review of Evidence to Date.
    Padhy SK; Takkar B; Narayanan R; Venkatesh P; Jalali S
    Appl Clin Genet; 2020; 13():179-208. PubMed ID: 33268999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?
    Dormegny L; Studer F; Sauer A; Ballonzoli L; Speeg-Schatz C; Bourcier T; Dollfus H; Gaucher D
    Heliyon; 2024 Feb; 10(3):e25154. PubMed ID: 38322949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.
    Ku CA; Igelman AD; Huang SJ; Bailey ST; Lauer AK; Duncan JL; Weleber RG; Yang P; Pennesi ME
    Transl Vis Sci Technol; 2024 Jun; 13(6):11. PubMed ID: 38888288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
    Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA
    JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
    Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
    Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.